RxDoctor Payments Data

Benjamin Margolis, MD

Psychiatry · Middletown, NYNPI 1770876922

Payments from drug & device makers

$570in general payments, 2019–2025

Across 19 payments — averaging $29.98 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Sunovion Pharmaceuticals Inc.$125
  • Otsuka America Pharmaceutical, Inc.$94
  • SK Life Science, Inc.$86
  • Teva Pharmaceuticals USA, Inc.$80
  • Johnson & Johnson$77
  • Greenwich Biosciences, Inc.$53
  • plus $54 from 2 others

What the payments were for

  • Food & beverage$570100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$570 in reported general payments places this provider in the 70th percentile of 3,713 psychiatry providers in New York.

See all psychiatry providers in New York

Medicare billing

Part B allowed, 2024
$116,998
Medicare patients
230
Services billed
1,279

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
AustedoDeutetrabenazine31$264,603
IngrezzaValbenazine Tosylate33$260,909
Abilify MaintenaAripiprazole52$150,751
RexultiBrexpiprazole98$146,964
Invega SustennaPaliperidone Palmitate13$45,887
Chlorpromazine Hcl133$45,024
Olanzapine842$42,000
Lupron DepotLeuprolide Acetate19$39,368
NuedextaDextromethorphan Hbr/Quinidine22$35,163
Risperdal ConstaRisperidone Microspheres14$35,044
FanaptIloperidone17$31,968
Atrovent HfaIpratropium Bromide62$30,606
Risperidone774$28,472
Divalproex Sodium562$28,323
Clozapine459$27,077

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Otsuka America Pharmaceutical, Inc.Abilify Maintena, Rexulti$94$297,715150 claims
Teva Pharmaceuticals USA, Inc.Austedo$80$264,60331 claims
Johnson & JohnsonInvega Sustenna, Risperdal Consta$77$80,93127 claims
AbbVieLupron Depot$34$39,36819 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 3,713 psychiatry providers in New York.

Other psychiatry in Middletown

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →